A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Key facts

Sponsor

Guangzhou Lupeng Pharmaceutical Company LTD.

Intervention

Rocbrutinib(drug)

Enrollment

150 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2028

Study locations (30)

• Anhui Cancer Hospital (West Branch of Anhui Provincial Hospital), Hefei, Anhui, China
• Beijing Shijitan Hospital, Beijing, Beijing Municipality, China
• Beijing Tongren Hospital, Beijing, Beijing Municipality, China
• National Cancer Center/Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
• Peking University Third Hospital, Beijing, Beijing Municipality, China
• The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• Fujian Cancer Hospital, Fuzhou, Fujian, China
• Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
• Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
• Nanfang Hospital, Guangzhou, Guangdong, China
• Meizhou People's Hospital, Meizhou, Guangdong, China
• Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
• The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
• The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
• The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07365306
  Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE3NCT07493109
  Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
  Ou Bai, MD/PHD
• RECRUITINGPHASE2NCT07493148
  Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
  Ou Bai, MD/PHD
• RECRUITINGPHASE3NCT07409428
  A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
  Hutchmed
• RECRUITINGPHASE2NCT07397832
  CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE3NCT07188558
  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
  Lyell Immunopharma, Inc.
• RECRUITINGPHASE2NCT07499271
  Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE2NCT07371923
  Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
  Beijing Tongren Hospital

See all trials for Diffuse large B-cell lymphoma →